Rethinking Product for Healthcare in the Age of AI

The first few generations of healthcare technology products followed a straightforward formula: take a workflow, digitize it, make it faster. Scheduling became online booking. Paper orders became CPOE. Fax referrals became electronic referrals. The product manager's job was to understand a workflow, design a better digital version of it, and ship it. The optimization target was efficiency within a single, isolated process.

That formula worked for what it was. But it also created the landscape we have now: thousands of point solutions, each optimizing its own narrow workflow, none of them connected in a way that lets you ask the question that actually matters. Did the patient get better? Did the system improve? Local processes got faster, but no one could measure whether those faster processes actually improved the outcomes multiple steps downstream that the enterprise truly cares about. There is plenty of anecdotal evidence that they did not.

An AI platform changes this. Not because AI is a better way to digitize workflows, but because it changes the fundamental optimization target. For the first time, product teams can build systems that directly optimize for patient outcomes and overall system performance, not just the efficiency of one isolated step. That shift changes almost everything about how product needs to work.

From Digitized Workflows to Outcome Optimization

The old model of healthcare product development treated each workflow as a self-contained problem. You studied how nurses do discharge planning, created a digital version of the existing process, and measured success primarily by whether nurses used it and whether they reported personal efficiency gains. But the questions that actually mattered to the health system went unanswered. Did patients get out faster? Did that result in higher throughput? Did readmissions go down? The evidence on whether these tools improved downstream outcomes is mixed at best. Research consistently shows stronger evidence for process-level improvements than for the end-state outcomes health systems actually care about.

This is the core limitation of the old paradigm: you digitized a process of unknown efficiency and unknown impact, then measured whether people adopted the digital version. The tools were static, rules-based, or built on predictive models that applied the same logic regardless of context. They could not adapt based on what was actually happening to patients, and different health systems serving different populations had no way to get different adaptations. The product was a faster version of the existing workflow. Whether the existing workflow was the right one to begin with was not a question the product could answer.

An AI platform makes it possible to directly address that question. Instead of building a "discharge planning tool," you can build a system that optimizes for what the health system actually cares about: getting patients through faster and making sure they do not need to come back. That system does not automate existing steps. It finds the steps, evaluates which ones matter, synthesizes patient data across fragmented sources, recommends tailored interventions, and learns from what actually happened after the patient left. Did they come back within 30 days? What was different about the cases that went well versus those that did not? And it can learn differently for different populations and different health systems, because true platforms support that configurability.

This is not a feature upgrade. It is a different kind of product entirely: one that closes the loop between decisions and outcomes.

What This Demands of Product

Building products that optimize for outcomes rather than workflow efficiency introduces challenges the healthcare technology industry has not had to confront.

The first is measurement. In historic software products, the feedback loop is behavioral: did the user click the button, did they complete the flow. Going forward, the feedback loop that matters is whether the steps that led to the intervention actually improved the outcome. Did the system's recommendation hold up when measured against what actually happened to the patient, bill, or contract weeks or months later? Evaluation design becomes a core product discipline, not something you hand off after launch. You need to define what "good" looks like in collaboration with clinicians and operational leaders before you build, and you need instrumentation that tells you whether you got there.

The second challenge is harder. When you can optimize for the end-state outcome, the existing series of workflows designed to get there are unlikely to be the best ones. The old approach mirrored existing processes. The new approach may need to fundamentally change them. If the data shows that the current process produces suboptimal results no matter how efficiently it runs, the product needs to propose a different process. Product leaders in healthcare AI need to think deeply about what is actually needed to optimize the outcome, and then use data to convince clinicians, operators, and executives (some of whose roles have historically been tied to the old way of doing things) that potentially meaningful changes are positive. 

It also means product teams must think carefully about what the system should not do. In consumer software, a wrong recommendation is an annoyance. In healthcare, it can erode trust in minutes that took months to build. Knowing where to draw the line between autonomous AI action and human judgment is one of the hardest product design questions in this space, and getting it wrong in either direction is costly.

Product as Connective Tissue: The Expanding Circle

Product management has always been a mix of vision and glue. The vision part is seeing what is possible and defining what to build. The glue part is bringing together the people who need to collaborate to make it real. Historically, that meant users, engineering, and design. In healthcare AI, the circle has expanded significantly.

Applied AI engineers are the new right hand. I wrote in my previous post about this emerging discipline. For product managers building AI-powered healthcare systems, these engineers are not downstream implementers who receive specs. They are co-designers who understand what models can and cannot do in specific contexts. The best product outcomes come from product and applied AI engineering working in tight iteration, where the engineer's understanding of system behavior directly shapes product direction.

Platform engineering now sets the architecture that AI runs in and is governed by. The choices a platform team makes about data layer design, orchestration infrastructure, and governance frameworks have direct implications for every AI product built on top. Product managers who treat platform as someone else's problem will design products that cannot be built as specified, or worse, products that work in a demo but fail under real operational conditions. I will have more to say about platform engineering in an upcoming post, but the key point here is that platform decisions are product decisions.

Data and context engineering have enormous AI product impact. What information an AI system sees, when it sees it, and how it is structured often determines whether the product works or does not. Product managers need enough literacy in retrieval strategies, context window management, and data pipeline design to have informed conversations about these tradeoffs. They do not need to build these systems, but they need to understand which product decisions depend on them.

Health system executives are now direct product stakeholders. When the potential impact of an AI product extends to clinical outcomes, operational performance, and organizational transformation, the people accountable for those outcomes (CMIOs, CIOs, CNOs, COOs) become genuine participants in product shaping, not just buyers who evaluate features. Their vision for what their organization needs to become is a product input that did not exist in the workflow-digitization era.

Engagement teams are product stakeholders, not just delivery vehicles. These teams are the primary points of contact into partner organizations, and they understand the operational reality that the product must survive in. Especially for initial product builds, the work must be done with a build partner where the engagement team and key customer stakeholders are brought along from the beginning. Without that, you end up with a product that has massive potential and zero adoption. Engineering change management into the product means designing not just for the end user in front of the screen, but for the organization that has to absorb and sustain the change.

The New Product Owner Super Powers (and the Responsibilities That Come With Them)

There is one more shift worth addressing directly, because it is happening fast.

Product owners can now build truly functional prototypes end to end, without an engineering team directly involved. With AI-powered coding tools, a product manager can go from idea to working prototype in hours, not weeks. This is genuinely transformative. Product leaders can express their vision in working software, get to alignment with stakeholders faster, and test assumptions before a single sprint is planned. The distance between "what I imagine" and "what you can interact with" has collapsed.

But this capability comes with a trap. A prototype that looks and feels like a product is not a product. It has not been reviewed for security. It has not been tested at scale. It has not been evaluated against the edge cases that healthcare environments produce constantly. The product owner who built it may not have the technical depth to know where the prototype's architecture would fail under load, where it introduces data exposure risks, or where the AI behavior would degrade in conditions the prototype never encountered. And in healthcare, there is an additional concern: prototyping often involves working with sensitive patient data or data structures that mirror real patient data. Without the right guardrails, the prototyping process itself can introduce data leakage risks before the product ever reaches engineering.

This is not a hypothetical concern. We are actively thinking about how to make this capability safe and productive at Qualified Health. Our approach: engineering provides clear constraints, best-practice patterns for coding tools, and sandboxed environments where product owners can build and experiment freely without introducing security vulnerabilities or architectural decisions that will be expensive to undo. The goal is to amplify what product owners can do while maintaining the rigor that healthcare demands.

An Invitation

Product for healthcare in the age of AI is a different discipline than what came before. The optimization target has changed, the feedback loops are deeper and more consequential, the circle of collaborators has expanded, and the tools product owners wield have become dramatically more powerful.

To health system leaders implementing vendor AI products or building your own: I am curious about your expectations for product impact in this new landscape. What do you expect from your technology partners? What do you expect from your leadership and frontline staff? What is working, and where are you stuck? Thinking back to the expanding circle above: what outcomes are you now most focused on having products optimize directly for?

If you are a product leader who thinks in systems, who wants to work at the intersection of AI capability and healthcare reality, and who is energized by the idea of building products that genuinely learn and improve, we are hiring across product at Qualified Health. Come build with us.